<code id='13065448E5'></code><style id='13065448E5'></style>
    • <acronym id='13065448E5'></acronym>
      <center id='13065448E5'><center id='13065448E5'><tfoot id='13065448E5'></tfoot></center><abbr id='13065448E5'><dir id='13065448E5'><tfoot id='13065448E5'></tfoot><noframes id='13065448E5'>

    • <optgroup id='13065448E5'><strike id='13065448E5'><sup id='13065448E5'></sup></strike><code id='13065448E5'></code></optgroup>
        1. <b id='13065448E5'><label id='13065448E5'><select id='13065448E5'><dt id='13065448E5'><span id='13065448E5'></span></dt></select></label></b><u id='13065448E5'></u>
          <i id='13065448E5'><strike id='13065448E5'><tt id='13065448E5'><pre id='13065448E5'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:knowledge    Page View:1598
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In